That does raise serious issues around the utility of passes. Passes under Delta made sense, because the transmission effects were so significant. When the transmission benefits are much more diminished because of the infectiousness of Omicron, the utility does diminish, and we deserve a conversation around under what circumstances passes and mandates will be required and, indeed, where they're useful. I understand that the DPMC review that will be going to Cabinet will be looking at those issues. Those are not easy issues. The science and the evidence is emerging on that, and we can look overseas to some of that evidence and see what's going to happen in New Zealand, because our trajectory is not that much different to other countries in terms of case numbers. And so we'll look at that, and we welcome that review. That's an issue that the House is going to have to grapple with in 2022. Thanks, Madam Speaker.